HEAL

HEAL remains in a Stage 2 advancing regime with clear higher highs and higher lows underpinned by an upward‐sloping 50 DMA. Despite a recent Bullish Exhaustion pattern, the pullback is resolving as corrective, holding into the 9/21 EMA zone. Neutral OB/OS supports patient entries, and volume dynamics continue to favor the uptrend. Buying the dip into rising EMAs aligns execution with medium‐term structure and momentum.

• ↑HEAL AUM ~$30.4M provides diversified exposure to health tech innovators
• ↑Top holdings like IQVIA and DexCom support robust revenue growth
• ↓YTD NAV down 9.4% underscores recent underperformance